Table 1.
Patient information and clinical features of the CR-hvKP isolates
| Strain Number | Patient Number | Age-range | Department | Collection Date | Source | Outcome | Resistance Determinants Genes | PFGE type | MLST |
|---|---|---|---|---|---|---|---|---|---|
| CS1 | P2 | 21–30 | ICU | 2016/12/27 | csf | Death | blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3 | A | 25 |
| CS11 | P1a | 41–50 | ICU | 2016/11/28 | sp | Survived | blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3 | A | 25 |
| CS12 | P1 | 41–50 | ICU | 2016/12/6 | sp | Survived | blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3 | A | 25 |
| CS15 | P3a | 51–60 | IMD | 2016/12/21 | sp | Survived | blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3 | A | 25 |
| CS17 | P4 | 71–80 | ICU | 2016/12/3 | sp | Giving up Treatmentb | blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3 | A | 25 |
| CS45 | P5 | 41–50 | ICU | 2016/11/15 | sp | Giving up treatment | blaKPC-2, blaTEM-1, blaCTX-M-3 | A | 25 |
| CS47 | P6 | 71–80 | ICU | 2016/12/28 | blood | Giving up treatment | blaKPC-2, blaTEM-1, blaCTX-M-3 | A | 25 |
| CS48 | P3 | 51–60 | IMD | 2016/12/31 | sp | Survived | blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3 | A | 25 |
| CS57 | P3 | 51–60 | IMD | 2017/3/11 | sp | Survived | blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-3 | A | 25 |
| CS60 | P14 | 61–70 | CSD | 2017/6/16 | puncture fluid | Giving up treatment | bla SHV-1 | H | 25 |
| CS61 | P15 | 31–40 | ICU | 2017/6/4 | drainage liquid | Death | bla SHV-1 | H | 25 |
| CS62 | P8 | 51–60 | ICU | 2017/6/16 | sp | Survived | bla SHV-1 | C | 25 |
| CS70 | P1 | 41–50 | RD | 2017/6/22 | sp | Survived | blaTEM-1, blaCTX-M-3 | A | 25 |
| CS80 | P13 | 61–70 | Burn Unit | 2017/7/2 | traumatic secretion | Death | blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-65 | G | 11 |
| CS90 | P9 | 51–60 | Outpatient | 2017/3/27 | drainage liquid | Survived | blaSHV-1, blaCTX-M-65 | D | 375 |
| CS103 | P11 | 41–50 | ICU | 2017/5/22 | sp | Giving up treatment | blaKPC-2, blaSHV-1 | F | 11 |
| CS118 | P12 | 71–80 | ICU | 2017/3/18 | sp | Giving up treatment | blaKPC-2, blaSHV-1, blaTEM-1, blaCTX-M-65 | F | 11 |
| CS127 | P10 | 41–50 | Outpatient | 2017/5/11 | blood | Survived | bla SHV-1 | E | 25 |
| CS129 | P1 | 41–50 | ICU | 2017/3/16 | sp | Survived | blaKPC-2, blaSHV-1, blaCTX-M-3 | A | 25 |
| CS59497 | P7 | 51–60 | ICU | 2014/10/5 | sp | Survived | blaNDM-1, blaSHV-1, blaTEM-1 | B | 25 |
Department: indicates the department at the Xiangya Hospital, where the samples were collected; ICU Intensive care unitm, IMD Integrative Medicine Department, CSD Cerebrovascular Surgery Department, RD Rehabilitation Department, mCIM Modified Carbapenem Inactivation Method, PFGE Pulsed Field Gel Electrophoresis, MLST Multilocus sequence type
“CSF” Cerebrospinal fluid, “Sp” Sputum
aPatients P1 and P3 are immunocompromised patients. Repeated infections occurred in these two patients during 2016 and 2017
bThe patient’s condition deteriorated so the patient stopped any further treatment